Leadership Overview
Simtra BioPharma Solutions has 4 executives leading key functions including strategy, information technology, financial management, and operational excellence.
Focused on delivering high-quality sterile injectables, Simtra BioPharma Solutions maintains a commitment to precision and transparency to ensure patient needs are met through reliable manufacturing standards.
Focused on delivering high-quality sterile injectables, Simtra BioPharma Solutions maintains a commitment to precision and transparency to ensure patient needs are met through reliable manufacturing standards.
Leadership Roles at Simtra BioPharma Solutions
Franco Negron - Chief Executive Officer
Franco Negron, the Chief Executive Officer at Simtra BioPharma Solutions, directs the overarching corporate strategy and long-term vision for the organization. Negron oversees the alignment of manufacturing capabilities with global pharmaceutical market demands, ensuring that sterile injectable production remains consistent with rigorous quality standards. By fostering a culture of transparency and precision, the Chief Executive Officer drives the company toward operational excellence and sustainable growth. Franco Negron maintains close collaboration with the Board to secure the resources necessary for expanding service offerings and product delivery options. This leadership role involves navigating complex regulatory landscapes while maintaining a focus on patient-centric outcomes. Through strategic oversight of all business units, the Chief Executive Officer ensures that the organization meets client requirements in full, consistently delivering high-value solutions that address evolving healthcare needs across international markets.
Tim Donovan - Chief Financial Officer
Tim Donovan, the Chief Financial Officer at Simtra BioPharma Solutions, manages the fiscal health and capital allocation strategies required to sustain high-precision manufacturing operations. Donovan oversees financial planning, budgeting, and risk management, ensuring that the company maintains the resources necessary for continuous investment in sterile injectable technology. By analyzing market trends and operational costs, the Chief Financial Officer drives financial performance and supports the expansion of service delivery options. Tim Donovan coordinates with the executive team to ensure that capital expenditures align with the company's commitment to quality and transparency. This leadership role involves maintaining rigorous financial controls and reporting standards that satisfy stakeholders while enabling long-term growth. Through the optimization of financial processes, the Chief Financial Officer secures the stability needed to meet evolving patient needs, ensuring that the organization remains a reliable partner in the pharmaceutical industry while achieving consistent profitability.
Raymond Guidotti - Chief Operating Officer
Raymond Guidotti, the Chief Operating Officer at Simtra BioPharma Solutions, directs the daily manufacturing activities and supply chain logistics for sterile injectable products. Guidotti oversees the production floor, ensuring that every detail meets the high standards of quality and precision required for pharmaceutical excellence. By managing the operational workflow, the Chief Operating Officer ensures that products are manufactured correctly the first time and delivered on schedule to meet client requirements. Raymond Guidotti drives continuous improvement initiatives across all facilities, focusing on efficiency and the scalability of service offerings. This leadership role involves close collaboration with the executive team to align operational capacity with market demand. Through the oversight of manufacturing processes and regional operational initiatives, the Chief Operating Officer maintains the company's reputation for reliability, ensuring that the organization consistently fulfills its mission to provide high-quality solutions for patients worldwide.
Mike Macrie - Chief Information Officer
Mike Macrie, the Chief Information Officer at Simtra BioPharma Solutions, architects the digital infrastructure and data security frameworks essential for high-precision pharmaceutical manufacturing. Macrie manages the integration of advanced technology systems that support sterile injectable production, ensuring data integrity and operational transparency across all facilities. By modernizing the digital landscape, the Chief Information Officer enables seamless communication between manufacturing units and client-facing platforms. Mike Macrie drives the implementation of scalable software solutions that optimize supply chain visibility and production scheduling. This leadership role involves coordinating with other C-suite members to align technological investments with the broader corporate mission of delivering quality products on time. Through the deployment of robust cybersecurity measures and data analytics, the Chief Information Officer protects critical intellectual property while enhancing the efficiency of global operations, ultimately supporting the company's commitment to meeting complex patient requirements.
Explore Leadership Teams in Manufacturing
Founded in 1974, Apotex is a proud Canadian, global pharmaceutical company that produces high-quality, affordable medicines (both generic and innovative pharmaceuticals) for patients around the world.
Company Leadership
DA
TM
Merz North America Inc is a company that operates in the Pharmaceuticals industry. It employs 1000to4999 people and has 500Mto1G of revenue. The company is headquartered in Raleigh, North Carolina.
Company Leadership
AS
JS
AS
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Company Leadership
CC
SR
United Therapeutics Corporation is a biotechnology company focused on the discovery, development, manufacturing, and commercialization of innovative therapies and advanced medical technologies for patients living with chronic, rare, and life-threatening diseases. The company is dedicated to addressing significant unmet medical needs by developing novel pharmaceutical treatments that improve patient outcomes and enhance quality of life
Company Leadership JR
JK
HH
Frequently Asked Questions Regarding Simtra BioPharma Solutions Top Executives and Leadership Team
